Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Clinical Gastroenterology and Hepatology(2020)10.1016/j.cgh.2020.07.012Source: DataRank Database

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab is a research paper published in Clinical Gastroenterology and Hepatology (2020). On theSindex it has a DataRank of 0. It has been cited 88 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

88 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 9.93)OA: closedTopics (37)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Paulo Gustavo Kotze ORCID,Alice Burgevin,Willam Tan,Alison T. Jess ORCID,Pei-Shun Li

Live enrichment

PubMed:32668338 OpenAlex:https://openalex.org/W3040762243

National Institutes of Health

Grant: P30 DK043351

Shire

Grant: unidentified

unidentified

Takeda Pharmaceuticals U.S.A.

AbbVie

Biogen

Bristol-Myers Squibb

Gilead Sciences

Sandoz

Pfizer

Tillotts Pharma

Boehringer Ingelheim

Genentech

Meso Scale Diagnostics

Shire

FWCI

9.93

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

closedLicense: Elsevier TDM

publisherhttps://api.elsevier.com/content/article/PII:S1542356520309733?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356520309733?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cgh.2020.07.012

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32668338

repositoryhttps://hal.univ-lorraine.fr/hal-04214950

Fields of Study

Inflammatory Bowel DiseaseLiver Diseases and ImmunityBiosimilars and Bioanalytical Methods03 medical and health sciences0302 clinical medicine

MeSH Terms

UstekinumabAlbertaColitis, UlcerativeGastrointestinal AgentsHumansRemission InductionRetrospective StudiesInflammatory Bowel DiseasesTreatment OutcomeAntibodies, Monoclonal, Humanized

Keywords

MedicineVedolizumabUstekinumabInternal medicineGastroenterologyInflammatory bowel diseaseInflammatory Bowel DiseasesAdalimumabTumor necrosis factor alphaDiseaseComparisonAnti-tnfIbdResponse To TherapyTreatment OutcomeGastrointestinal AgentsRemission InductionHumansColitis, UlcerativeAntibodies, Monoclonal, HumanizedAlbertaRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

FAIR Checklist

Authors (12)

Funding (14 grants)

Impact

Open Access

Topics